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ABSTRACT
The human APOBEC3 proteins are DNA cytidine
deaminases that impede the replication of many
different transposons and viruses. The genes that
encode APOBEC3A, APOBEC3B, APOBEC3C,
APOBEC3D, APOBEC3F, APOBEC3G and
APOBEC3H were generated through relatively
recent recombination events. The resulting high
degree of inter-relatedness has complicated the
development of specific quantitative PCR assays
for these genes despite considerable interest in
understanding their expression profiles. Here, we
describe a set of quantitative PCR assays that spe-
cifically measures the mRNA levels of each
APOBEC3 gene. The specificity and sensitivity of
each assay was validated using a full matrix of
APOBEC3 cDNA templates. The assays were used
to quantify the APOBEC3 repertoire in multiple
human T-cell lines, bulk leukocytes and leukocyte
subsets, and 20 different human tissues. The data
demonstrate that multiple APOBEC3 genes are ex-
pressed constitutively in most types of cells and
tissues, and that distinct APOBEC3 genes are
induced upon T-cell activation and interferon
treatment. These data help define the APOBEC3
repertoire relevant to HIV-1 restriction in T cells,
and they suggest a general model in which
multiple APOBEC3 proteins function together to
provide a constitutive barrier to foreign genetic
elements, which can be fortified by transcriptional
induction.
INTRODUCTION
The APOBEC3 (A3; apolipoprotein B mRNA-editing
enzyme, catalytic polypeptide-like 3) proteins are Zn
2+-
dependent DNA cytidine deaminases, which are capable
of inhibiting the replication of an incredible range of
mobile genetic elements (1–4). In humans, representative
A3 substrates include exogenous retroviruses such as
HIV-1 and HTLV, endogenous retroviruses such as
HERV, endogenous retrotransposons such as L1 and
Alu, and DNA viruses such as HBV and HPV (5–15).
Despite the relevance of many of these parasitic elements
to human health, the A3 proteins that function in vivo
against each particular element have yet to be deﬁned.
For instance, A3F and A3G have been shown to
strongly restrict HIV-1 in vitro and very likely contribute
to HIV-1 restriction in vivo, but strong arguments have
also implicated several other human A3 proteins (1–4,16).
The seven A3 genes are positioned in tandem on human
chromosome 22: A3A, A3B, A3C, A3D (formerly A3DE),
A3F, A3G and A3H (17). A deﬁning feature of each A3
gene is that it encodes a protein with one or two conserved
zinc (Z)-coordinating deaminase domains. Each Z domain
belongs to one of three distinct phylogenetic groups: Z1
(A3A and the C-terminal halves of A3B and A3G), Z2
(A3C, both halves of A3D and A3F, and the N-terminal
halves of A3B and A3G) and Z3 (A3H) (18). Based on the
relatedness of these Z domains, the human A3 repertoire
appears to be the result of a minimum of eight unequal
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occurred during the radiation of primates (18). The net
result is that the human A3 mRNAs share considerable
identity, ranging from 30% to nearly 100% (Figure 1A
and Supplementary Table S1). For example, nt 1–473 of
the A3F mRNA are 98.7% identical to A3G nt 50–522.
Similarly, A3A nt 259–937 are 96.6% identical to the cor-
responding region of A3B, nt 692–1370. The A3 genes are
also under positive selection and accordingly are highly
polymorphic (19–21). These inter-domain identities and
polymorphisms present considerable challenges to A3 ex-
pression proﬁling and quantiﬁcation.
Here we report speciﬁc quantitative PCR (qPCR) assays
for each of the seven human A3 cDNA sequences. We use
these assays to proﬁle the expressed A3 repertoire in
common T-cell lines, primary CD4
+ T lymphocytes, and
20 distinct human tissues. We also quantify the eﬀects of
T-cell stimulation and interferon (IFN) induction on A3
expression. These expression data indicate that several A3
proteins, in addition to A3F and A3G, are expressed in
CD4
+ cells and are therefore positioned to contribute to
HIV-1 restriction. More generally, nearly every cell type
and tissue expresses multiple A3s, consistent with a model
in which parasitic elements must evolve ways to cope with
a constitutive set of restriction factors that can be further
fortiﬁed by transcriptional induction.
MATERIALS AND METHODS
Cell lines
Human T-cell lines were cultured in RPMI (Thermo-
Fisher) supplemented with 10% fetal bovine serum
(Denville). SupT1 and H9 were obtained from the AIDS
Research and Reference Reagent Program. SupT11 is a
sub-clone of SupT1 obtained by limiting dilution. CEM
and CEM-SS were described (22).
Enrichment and culture of primary cells
Peripheral blood mononuclear cells (PBMCs) were
isolated from blood (Memorial Blood Center, St. Paul,
MN) by Ficoll-Paque gradient centrifugation (GE
Healthcare). The resulting buﬀy coat was subjected to
negative selection to enrich for naı¨ve primary CD4
+ T
cells (Miltenyi Biotech). Primary cells were cultured in
RPMI supplemented with 10% FBS and stimulated to
proliferate with 50Uml
 1 recombinant interleukin-2
(IL-2; Sigma), and 10mgml
 1 phytohemagglutinin
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Figure 1. A panel of quantitative PCR assays to monitor APOBEC3 mRNA levels. (A) Overview of A3 mRNA features. Each A3 mRNA is
depicted to scale except 2100nt of the A3F 30 UTR are not shown. Inter-A3 regions of 90% or greater identity over >18nt are highlighted in color.
(B) A histogram depicting the results of running each A3 qPCR assay against each of the seven A3 cDNA control templates. (C) A graph showing
the A3 qPCR assay ampliﬁcation ranges and eﬃciencies. The mean and standard deviation of two independent experiments each consisting of three
replica reactions is shown (in most instances the error is smaller than the symbol).
Nucleic Acids Research, 2010,Vol.38, No. 13 4275(PHA; Fisher Healthcare). To conﬁrm proliferation, 10
6
cells were stained with 10mM carboxyﬂuorescein diacetate
succinimidyl ester (CFSE) according to the manufacturer
(Invitrogen) and analyzed by ﬂow cytometry. PBMCs and
CD4
+ T cells were treated with 2ngml
 1 universal type I
IFN (R&D Systems).
RNA preparation
PBS-washed cells were prepared for RNA isolation by
lysis in ice-cold buﬀer RLT (Roche) supplemented with
10mlml
 1 2-mercaptoethanol (Sigma). RNA was isolated
using the RNeasy kit (Qiagen). Two optional components
of the kit, QiaShredder and on-column DNase digestion,
were used to homogenize lysates and remove genomic
DNA. RNA concentrations were determined spectroscop-
ically and RNA quality was assessed by gel analysis
(Supplementary Figure S1). Total RNA from 20 distinct
tissues, each from a minimum of three donors, was
purchased from Ambion. The control qPCRs for house-
keeping genes (below) were similarly eﬃcient for all RNA
preparations, indicating equally high qualities and
integrities.
cDNA synthesis
Total RNA (1mg) was used to synthesize cDNA using
avian myeloblastosis virus reverse transcriptase (AMV
RT; Roche) and random hexameric primers. We found
that random hexamer mRNA priming was preferable to
oligo-dT priming, which resulted in ineﬃcient synthesis of
some A3 cDNAs, particularly A3D and A3F, most likely
because of their long, repeat-rich 30 untranslated regions
(UTRs) (Figure 1A and Supplementary Figure S2). cDNA
synthesis reactions were performed by mixing 3mlo f
333mM random hexamer primer (50mM ﬁnal concentra-
tion) with 1mg of total RNA diluted in 10ml of RNase-
free water. This mixture was heated for 10min at 65 Ct o
remove RNA secondary structure and then cooled brieﬂy
on ice. Master mix (7ml) containing 0.5ml Protector
RNase inhibitor (Roche), 0.4ml AMV RT, 4ml5   AMV
RT reaction buﬀer, and 2.1ml dNTPs (Roche, 10mM
each;  1mM each ﬁnal concentration) were then added
to these reactions, which were subsequently incubated at
25 C for 10min, 42 C for 1h, then 95 C for 5min.
Reactions were then diluted by addition of 80ml
RNase-free H2O, and used in qPCR reactions.
qPCR
cDNAs levels were quantiﬁed by PCR using a Roche
Lightcycler 480 instrument according to the manufactur-
er’s protocols. Reactions were performed in 96-well plates
with each containing 7.5ml2   probe master mix (Roche),
1.25mlH 2O, 1.05ml primers (5mm each), 0.2ml UPL probe
(Roche) and 5ml cDNA (prepared as above). Reactions
were incubated at 95 C for 10min, then 40 cycles of 95 C
for 10s, 58 C for 15s, then 72 C for 2s. Table 1 lists the
full sequences of all primers and probes used in this study;
the design rationale and validation experiments are
described below. The PCR cycle at which ampliﬁcation
was detectable above a background threshold (threshold
cycle, or Ct) was calculated with the maximum second
derivative method using the Lightcycler 480 software
(Roche, version 1.5.0). cDNA was synthesized and
qPCR performed in triplicate for each sample, and the
mean values and standard deviations for each triplicate
are reported.
Primer design
Primer pairs were designed to avoid inter-A3 identity
and only amplify the intended A3 target (Figure 1A,
Supplementary Figure S2, Table 1 and Supplementary
Table S1). Primer pair speciﬁcity was veriﬁed by
manually inspecting alignments of primers and A3
cDNA sequences, by using BLAST (version 2.2.20;
http://blast.ncbi.nlm.nih.gov/) and Primer-BLAST
software (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/; default parameters except E set to 1) and, experi-
mentally, by attempting to amplify 10
4 copies of every A3
control template with each set of A3 qPCR primers
(Figure 1B). Primers were additionally designed to have
similar melting temperatures and were conﬁrmed to have
similar reaction eﬃciencies (Figure 1C and see below).
Furthermore, primers were designed such that they
Table 1. APOBEC3 qPCR primers and probes
Gene symbol mRNA NCBI
accession
50 Primer
Name
Seq (50–30)3 0 Primer
name
Seq (50–30) Probe
name
Seq
a
APOBEC3s
APOBEC3A NM_145699 RSH2742 gagaagggacaagcacatgg RSH2743 tggatccatcaagtgtctgg UPL26 ctgggctg
APOBEC3B NM_004900 RSH3220 gaccctttggtccttcgac RSH3221 gcacagccccaggagaag UPL1 cctggagc
APOBEC3C NM_014508 RSH3085 agcgcttcagaaaagagtgg RSH3086 aagtttcgttccgatcgttg UPL155 ttgccttc
APOBEC3D NM_152426 RSH2749 acccaaacgtcagtcgaatc RSH2750 cacatttctgcgtggttctc UPL51 ggcaggag
APOBEC3F NM_145298 RSH2751 ccgtttggacgcaaagat RSH2752 ccaggtgatctggaaacactt UPL27 gctgcctg
APOBEC3G NM_021822 RSH2753 ccgaggacccgaaggttac RSH2754 tccaacagtgctgaaattcg UPL79 ccaggagg
APOBEC3H NM_181773 RSH2757 agctgtggccagaagcac RSH2758 cggaatgtttcggctgtt UPL21 tggctctg
Reference genes
TBP NM_003194 RSH3231 cccatgactcccatgacc RSH3232 tttacaaccaagattcactgtgg UPL51 ggcaggag
RPL13A NM_012423 RSH3227 ctggaccgtctcaaggtgtt RSH3228 gccccagataggcaaactt UPL74 ctgctgcc
HPRT1 NM_000194 RSH2959 tgaccttgatttattttgcatacc RSH2960 cgagcaagacgttcagtcct UPL73 gctgagga
aIt is not known whether the UPL probes correspond to the coding or template DNA strands of their target sequences (Roche proprietary
information).
4276 Nucleic Acids Research, 2010,Vol.38, No. 13would amplify all described variants of each A3 mRNA
(i.e. splice variants and SNPs; data not shown). Design
was assisted by the Roche ProbeFinder software (version
2.43; http://qpcr.probeﬁnder.com/roche3.html) and by
Primer3 software (version 0.4.0; http://primer3.
sourceforge.net/).
Data analysis
Expression level normalization. A3 expression data were
normalized to the expression of TATA-box binding
protein (TBP; see below). Essentially identical normalized
results were obtained using ribosomal protein L13A
(RPL13A), or hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) (data not shown). None of these
controls showed altered expression levels upon treatment
of cells with IL-2, PMA and/or IFN.
Determination of reaction eﬃciencies. For all assays, the
primer eﬃciency was determined using serial dilutions of
control templates (e.g. Figure 1C). The control templates
consisted of portions of the 50 UTRs and coding regions of
the A3 cDNAs ampliﬁed by PCR and cloned into
pCR2.1-TOPO (Invitrogen). The same templates were
used to validate assay speciﬁcity (Figure 1B). These
plasmids were linearized by digestion with XmnI or
BglII, phenol–chloroform extracted, ethanol precipitated,
and the DNA concentration was determined spectroscop-
ically. Ten-fold serial dilutions of these plasmids were
prepared with 10
1–10
8 plasmid molecules per 5ml. These
dilutions were used as templates in qPCR reactions. Ct
values were plotted against the log10 number of template
molecules in each reaction (Figure 1C), and the slope of
this line determines the reaction eﬃciency according
to the equation: eﬃciency=10
( 1/slope) (23). Reaction
eﬃciencies were also calculated from the actual ampliﬁca-
tion curves from several experiments (24). Reaction
eﬃciencies calculated by these two methods agreed
closely (data not shown).
The reaction eﬃciencies (E) determined in this manner
were then used to calculate relative expression levels
between two samples (S1 and S2), normalized to a refer-
ence gene (ref, TBP), according to published methods (23):
Ct(A3)=CtA3,S1 CtA3,S2
Ct(ref)=Ctref,S1 Ctref,S2
Relative expression=(EA3)
 Ct(A3)/(Eref)
 Ct(ref)
Immunoblotting
Cells were cultured and/or isolated as described above,
washed in PBS and lysed in 0.2% NP40 buﬀer with
1 EDTA-free protease inhibitor mixture (Roche).
Proteins were subjected to ice-cold acetone precipitation
prior to quantiﬁcation (Bio-Rad). An equal amount of
protein was fractionated on a 10% SDS-polyacrylamide
gel and transferred to a PVDF membrane (Millipore).
Membranes were blotted with antibodies speciﬁc to
A3F, A3G or tubulin (Covance). The A3F and A3G poly-
clonal antibodies were obtained from the AIDS Research
and Reference Reagent Program courtesy of M. Malim
(Kings College London) and J. Lingappa (University of
Washington), respectively (25,26). Band intensities were
quantiﬁed using Image J software (NIH).
RESULTS
APOBEC3 qPCR assay designs and optimization
experiments
To determine where and when each A3 mRNA is ex-
pressed we developed a panel of speciﬁc qPCR assays.
For each assay, several computational and manual pro-
cedures were used to develop speciﬁc and eﬃcient qPCR
primers. Each primer was selected to span two exons
(Figure 1A and Table 1). The primers and probes were
screened to avoid known single nucleotide polymorphisms
and splice variations (data not shown). Assay speciﬁcity
was tested by pitting all seven qPCR probe/primer
sets against each of the seven A3 cDNA templates in
a 49-reaction qPCR matrix. The ampliﬁcation results
demonstrated that each assay was speciﬁc to the
intended target A3 (Figure 1B).
The next most important parameter to test and optimize
was reaction eﬃciency. Serial dilutions of linearized A3
control cDNA templates were used in qPCR reactions
to measure eﬃciencies. After as many as four primer/
probe redesigns for some A3s, high eﬃciencies ranging
from 1.97–1.99 were achieved for each qPCR assay
(Figure 1C). These nearly ideal eﬃciencies indicated that
each assay would provide a robust and quantitative
measure of the level of expression of each A3 gene.
In other words, these data indicated that quantitative
comparisons of each A3 relative to the others are possible.
Assay standardization and normalization are crucial
parameters to ensure quantitative data set comparisons.
We therefore also designed and tested qPCR assays for
three common housekeeping genes, TBP, RPL13A and
HPRT (‘Materials and Methods’ section). The mRNA
levels of each of these genes were consistent between cell
types and tissues. To facilitate data normalization and
comparisons, only one of these genes (TBP) was used as
an internal standard.
Finally, each of the aforementioned A3 qPCR assays
was evaluated on two independent platforms to ensure
that all data could be reproduced and generalized. The
Roche Lightcycler 480 platform, which uses ﬂuorescent
probes, was used to develop the assays and for all data
reported here. A similar set of reaction speciﬁcities was
observed using diﬀerent instrumentation and detection
methods (iCycler and SybrGreen, respectively; BioRad,
data not shown). These data indicated that our A3
qPCR assays could be applied to a range of experimental
questions.
APOBEC3 expression proﬁles in permissive and
non-permissive T-cell lines
Three groups independently discovered A3G in 2002
(5,17,27). One of these studies was based on the observa-
tion that there are two distinct phenotypes in human
T-cell lines with respect to Vif-deﬁcient HIV-1 infection
(5,28–30). Cell lines such as CEM and H9 are resistant to
infection by Vif-deﬁcient viruses and, accordingly, are
Nucleic Acids Research, 2010,Vol.38, No. 13 4277termed non-permissive. On the other hand, cell lines such
as CEM-SS (a clonal derivative of CEM) and SupT1
support HIV-1 replication in the presence or absence of
Vif and are thus deemed permissive. A3G was originally
identiﬁed as the dominant restriction factor whose
presence accounted for the non-permissive phenotype
of CEM cells in comparison to its permissive daughter
line, CEM-SS. Since then, overexpression of several A3
family members has been shown to render CEM-SS
non-permissive to Vif-deﬁcient HIV replication
(1–5,16,22). Despite the elegance of this permissive
and non-permissive dichotomy, the full nature of the
Vif-deﬁcient HIV-1 replication defect on non-permissive
cells has not been elucidated. In other words, which A3s
are required for HIV-1 restriction in non-permissive cells:
A3G or some combination of A3G and these other A3
proteins?
To shed additional light on this important question, we
proﬁled the expressed A3 repertoire in the two related cell
lines, non-permissive CEM and permissive CEM-SS.
These cell lines were used to clone A3G by subtractive
hybridization (5) and, as expected, A3G mRNA levels
were 12-fold higher in the non-permissive line CEM
(Figure 2A). However, levels of A3B, A3C, A3D and
A3F were also signiﬁcantly higher than those in
CEM-SS, by 19-, 2-, 3- and 28-fold, respectively. These
observations suggest that other A3s, in addition to A3G,
may contribute to Vif-deﬁcient HIV-1 restriction in CEM.
However, the presence of signiﬁcant A3C mRNA levels in
CEM-SS is concordant with it alone not being suﬃcient to
restrict the replication of Vif-deﬁcient HIV-1 (31,32).
Further consistent with the possibility that multiple A3s
contribute to the non-permissive phenotype, the
non-permissive T-cell line H9 was also found to express
multiple A3 mRNAs at levels well beyond those in per-
missive cells (Figure 2B). A3C, A3D, A3F, A3G, and A3H
were 2-, 8-, 16-, 19- and 1000-fold above those in CEM-SS
cells, respectively. In contrast to CEM cells, A3B was vir-
tually absent, and A3H was well expressed (considered
further below). Notably, the expression levels of all
seven A3 genes were extremely low and approaching
detection limits in the permissive line SupT11. Thus far,
SupT11 is the only T-cell line that we have found that is
practically devoid of A3 gene expression. The molecular
explanation for this is not known, but it is not due to
deletion of the locus because speciﬁc qPCR products are
still detected.
APOBEC3 expression proﬁles in primary leukocytes
Next we sought to deﬁne the A3 repertoire in fresh,
unstimulated PBMCs (Figure 2B). Multiple A3s were
expressed in PBMCs with the overall pattern resembling
that of CEM and H9 non-permissive lines (signiﬁcant
levels of A3C, A3D, A3F and A3G). However, some
major diﬀerences were detected. First and most strikingly,
PBMCs were found to express high A3A levels, which
were  5000-fold greater than CEM. These observations
were consistent with recent reports indicating that
A3A expression is speciﬁc to the CD14
+ lineage, which
includes macrophages and monocytes (11,33–35).
Second, PBMCs expressed virtually no A3B mRNA,
which is  100-fold less than CEM. Third, PBMCs ex-
pressed 4-fold more A3G than CEM, and 40-fold more
than CEM-SS. Finally, PBMCs were found to express
high levels of A3H, similar to those observed in H9,
 13-fold more than CEM, and nearly 1000-fold more
than CEM-SS or SupT11.
The expressed APOBEC3 repertoire in naı¨ve and
stimulated CD4
+ T lymphocytes
CD4
+ T lymphocytes are a major target of HIV-1. To
deﬁne the expressed A3 repertoire in this important
T-cell subset, we used negative selection to isolate CD4
+
lymphocytes from fresh PBMCs (Figure 3A). These cells
were stimulated with IL-2 and PHA and shown to prolif-
erate by CFSE staining and ﬂow cytometry (Figure 3B).
T-cell stimulation caused the induction of every A3 with
the exception of A3A (Figure 3C). Mitogen activation had
been shown previously to induce A3G expression in CD4
+
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Figure 2. APOBEC3 expression in human T-cell lines and naı¨ve
PBMCs. (A) A3 expression in the permissive T-cell line CEM-SS and
the non-permissive line CEM. Mean values and standard deviations of
three independent qPCR reactions are shown for each condition.
Expression is normalized to the reference gene TBP and the level of
CEM-SS A3G is set to 1 to facilitate comparison (denoted by the
asterisk). (B) A3 expression in the permissive T-cell lines SupT11 and
CEM-SS in comparison to non-permissive lines CEM and H9. The
expressed A3 repertoire in PBMCs is shown for comparison (data
from an independent experiment in which CEM and CEM-SS yielded
results similar to those shown here). The experimental parameters are
identical to those used in panel A.
4278 Nucleic Acids Research, 2010,Vol.38, No. 13T cells (35,36). The increase in A3H expression levels is
particularly remarkable, rising 22-fold over naı¨ve levels.
Several APOBEC3s are IFN-responsive
In response to viral infection, cytokines such as type I
IFNs are induced, and these in turn activate the expression
of hundreds of genes. Several A3s have been shown to be
IFN-responsive, but only two reports have considered the
entire A3 repertoire and procedures have varied consider-
ably [(11,35,37–43); see ‘Discussion’ section]. To extend
this work, fresh PBMCs were treated with leukocyte
IFN and the resulting A3 mRNA levels were quantiﬁed
by qPCR (Figure 4A). In bulk PBMCs, A3A was clearly
induced, in agreement with prior reports (11,35,40,44).
The other A3s were also found to be up-regulated but to
lesser extents.
We next examined the eﬀects of IL-2, PHA and IFN on
A3 expression in naı¨ve and stimulated CD4
+ T cells
(Figure 4B). As shown above, the T-cell mitogens IL-2
and PHA induced the mRNA levels of all of the A3s
except A3A (compare Figures 3C and 4B). In contrast,
IFN treatment did little to alter these expression proﬁles.
Thus, the A3s in CD4
+T lymphocytes are not IFN indu-
cible, whereas the A3s in at least one other PBMC cell type
are IFN-responsive. Based on recent reports, CD14
+
phagocytic cells such as monocytes and macrophages are
likely to be the only leukocyte subset in which A3 expres-
sion is IFN-inducible [(11,35,40,44) and data not shown].
APOBEC3 expression proﬁle in human tissues
An important question with respect to A3 expression is
whether or not it is conﬁned to immune cell compart-
ments. To help address this issue, we quantiﬁed the ex-
pressed A3 repertoire of twenty normal human tissues.
Two cell lines, CEM and SupT11, and fresh PBMCs
were assayed in parallel to facilitate comparisons with
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Figure 3. APOBEC3 expression in naı¨ve and stimulated CD4
+
lymphocytes. (A) Flow cytometry histograms depicting the results
of CD4
+ lymphocyte puriﬁcation by negative selection. (B) Flow
cytometry histograms of CFSE-labeled cells 4 days after mock or
IL-2/PHA treatment, naı¨ve and stimulated, respectively. (C) A3 expres-
sion in naı¨ve and 3day stimulated CD4
+lymphocytes. Data from CEM
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and standard deviations of three independent qPCR reactions are
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Figure 4. IFN induces APOBEC3 expression in PBMCs but not CD4
+
T cells. The relative A3 mRNA levels in (A) PBMCs and (B) CD4
+ T
lymphocytes treated for 48h with IL-2/PHA and/or IFN. Expression is
normalized to TBP and the naı¨ve A3H level is set to 1 (denoted by the
asterisk). Mean values and standard deviations of three independent
qPCR reactions are shown for each condition.
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emerged from these studies (Figure 5).
First, consistent with central roles in innate immunity,
A3 expression levels were high in lymphoid organs such as
the thymus and spleen. The thymus, which is rich in T
lymphocytes, has an expressed A3 repertoire similar to
that of primary CD4
+ T cells: low A3A and A3B, high
A3C, A3D, A3F, A3G and A3H (compare Figures 5 and
3C). The spleen is rich in both B and T lymphocytes, but it
is also a major reservoir for undiﬀerentiated monocytes
(45). This helped reconcile observations showing that the
spleen has relatively high levels of all seven A3s, consistent
with previous observations indicating that A3A is re-
stricted to CD14
+ cells including monocytes (11,35,40).
Second, many A3s were clearly expressed outside of the
blood compartment or common immune tissues. For
example, ﬁve of seven A3s showed peak expression levels
in lung tissue: A3A, A3B, A3C, A3D and A3H. The most
remarkable was A3A, which was detected at levels 70-fold
higher in the lung than the median value from all 20
tissues. This observation is consistent with large
numbers of CD14
+ macrophages residing in lung alveoli.
A bronchoalveolar lavage cell preparation from a
non-smoking individual yields 1 10
7 cells, of which
90–95% are macrophages (46). In addition, A3A was
expressed in adipose tissue at levels 5-fold higher than
the median value. This level is compatible with the
ﬁnding that adipose from an obese individual is 40%
macrophages by weight (47). Also of note is A3 expression
in the ovary. Levels of A3C, A3F and A3G were 3-, 5- and
nearly 3-fold higher, respectively, than median values
from the other tissues. This may indicate a requirement
for viral and transposable element restriction in female
germ cells (48).
Finally, some tissues expressed virtually no A3s. The
brain and the testes, for instance, had low A3 levels com-
parable to those of SupT11 (compare Figures 5 and 2B).
These are largely immune privileged organs that are
physically separated from other tissues and from potential
pathogen infections by the blood–brain barrier and the
blood–tubular barrier, respectively. The apparent A3 ex-
pression deﬁciency in these tissues may also be due in part
to the absence of appropriate gene expression activators
such as IFNs, cytokines and/or growth factors.
Strong correlations between APOBEC3 mRNA and
protein expression levels
To ask whether the observed APOBEC3 mRNA levels
correlate with protein levels, we separated cell extracts
by SDS–PAGE and probed the resulting blots with
antibodies raised against A3F and A3G (Figure 6). The
A3F polyclonal antibody is speciﬁc to the best of our
knowledge [(22,25) and unpublished observations]. The
A3G polyclonal antibody is semi-speciﬁc as it reacts
with both A3A and A3G, but these proteins are distin-
guishable by size (11,26,35).
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Figure 5. APOBEC3 expression in human tissues. A summary of qPCR data showing the relative A3 mRNA levels in the indicated cells and tissues.
The color scheme provides qualitative information, as the full range of blue (low expression) to red (high expression) color is used for each row of
data. The inset numbers represent the relative levels of each A3 mRNA across the panel with the median value in each row set to 1. Since the assay
eﬃciencies are almost identical (Figure 1C), these quantitative data can be used to compare any of the values within the table. Three replicas were
done for each condition and the average values were used to construct the table (the errors were <10% and are not shown for simplicity).
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Figure 6. APOBEC3 immunoblots. (A) T-cell line or (B) primary
CD4
+ lymphocyte (IL-2/PHA or mock treated) protein extracts were
examined by immunoblotting with antibodies speciﬁc to A3F or A3G.
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prior studies, A3F and A3G protein levels are consider-
ably lower in CEM-SS than they are in the non-permissive
lines CEM [e.g. Figure 6A; (22,49)]. The low but still
measurable levels of A3G in the CEM-SS population
also enabled quantiﬁcation by densitometry, revealing a
5–10-fold diﬀerence at the protein level between these two
lines. This value closely resembles the 10-fold diﬀerence
in A3G mRNA levels between CEM and CEM-SS
(Figure 2). In further agreement with our qPCR data,
A3G protein was too low to detect by immunoblotting
in SupT11 and  1.6-fold higher in H9 than CEM. As
for A3F, nearly equivalent protein levels were observed
in H9 and CEM, and it was undetectable in SupT11 and
CEM-SS (Figures 2 and 6A). Finally, we compared the
protein expression of A3F and A3G in primary CD4
+ T
lymphocytes under naı¨ve and stimulated conditions.
Consistent with our qPCR data, A3F was induced
slightly and A3G levels increased  2-fold upon T-cell
stimulation (Figures 3C and 6B). Overall, we conclude
that strong correlations are evident between the qPCR
results and the immunoblot data.
DISCUSSION
Despite remarkable progress identifying A3 restriction
substrates such as HIV-1, transposons, and foreign
DNA, the overarching biological functions of the A3 rep-
ertoire are still being elucidated (1–5,11,50). What events
drove the rapid expansion of the A3 locus to encode seven
A3 proteins, and a total of eleven zinc-coordinating
domains? Does each A3 protein serve some unique, diver-
gent function or do they serve the same function only in
diﬀerent places and/or at diﬀerent times? How much re-
dundancy exists? How much speciﬁcity? How much of this
is governed by transcriptional programs? To begin to
address the latter question, in particular, here we report
qPCR assays that enable the speciﬁc and quantitative de-
tection of the entire seven gene human A3 repertoire. We
have improved on previous commercial methods by re-
porting the identity, speciﬁcity and eﬃciency of each A3
primer/probe set, by demonstrating the assay’s function-
ality and usefulness across detection platforms and,
most importantly, by quantifying A3 expression in
multiple human tissues and cell types. During the course
of completing our experiments, an independent study on
A3 expression in hematopoietic cells and tissues was pub-
lished by Koning et al. (35). These two studies are largely
complementary, but some diﬀerences merit discussion.
The ﬁrst point is technical. We developed our own
qPCR assays and, as such, were able to ensure target spe-
ciﬁcity and near identical reaction eﬃciencies (Figure 1).
We also report the nucleotide sequences of the primers
and probes so the assays are fully compatible with many
diﬀerent qPCR methods and instruments (Table 1). In
contrast, Koning et al. used proprietary primers and
probes from Applied Biosystems, which are optimized
for speciﬁc reagents and instrumentation and less readily
adaptable to other platforms. Knowledge of the primer
binding sites is also crucial for detecting and ultimately
ascertaining the function of alternatively spliced A3
variants.
Second, our study uniquely focuses on the question of
which A3s are expressed in such a manner that they may
contribute to HIV-1 restriction in vivo. The observation
that the non-permissive T-cell lines CEM and H9
express signiﬁcantly higher levels of A3G and A3F is not
surprising (Figure 2). However, what is notable is that six
A3s (i.e. all but A3A) are expressed at higher levels in these
non-permissive cell lines. The constitutive A3 repertoire in
H9 appears remarkably similar to the induced repertoire
in stimulated, primary CD4
+ T lymphocytes (Figures 2B
and 3C). A3H levels, in particular, increase over 20-fold
upon T-cell stimulation with IL-2 and PHA. Together
with prior cell culture overexpression studies indicating
that A3H can restrict HIV-1 in a Vif susceptible manner
(20,51–55), our expression data strengthen the case that
A3H may contribute to HIV-1 restriction in vivo.I n
contrast, a role for A3A in HIV-1 restriction in CD4
+ T
cells is unlikely, because it is not expressed in this cell type
and it does not restrict Vif-deﬁcient HIV-1 in
overexpression experiments [this study and
(11,31,33,35)]. Unambiguously testing the involvement of
other A3s in HIV-1 restriction, in addition to A3F and
A3G, will require much further work.
Third, based on an extensive survey of A3 expression in
20 tissues, we conclude that the A3 mRNAs are expressed
broadly and not conﬁned to cells of the immune compart-
ment (although there is clearly some bias to immune cell
types; Figure 5). For example, adipose, colon, cervix,
bladder and the heart all express at least two A3sa t
levels 2-fold above the median among all tissues. In
partial contrast, Koning et al. concluded that, apart
from germ cell tissues, A3 expression is conﬁned to the
hematopoietic compartment and that their detection in
many tissues is simply due to inﬁltrating leukocytes (35).
This is likely the case for some tissues such as lung and
adipose where signiﬁcant numbers of A3A-expressing
macrophages are found. Although the true breadth of
A3 expression in human tissues (and a diﬀerent develop-
mental stages) will not be fully appreciated until suitably
speciﬁc immunohistochemistry antibodies are developed,
at least two additional lines of evidence support the like-
lihood that A3s are expressed broadly. First, as noted by
Koning et al. and as is also evident in our data sets, the
A3G mRNA levels typically exceed those of A3F in
PBMCs and in speciﬁc leukocyte types [Figures 3C, 4
and 5; (35)]. This ratio is inverted in some tissues such
as the cervix, colon and ovary, strongly suggesting that
immune cell inﬁltration is not the whole story [Figure 5
and (35)]. Second, many clonally derived cancer cell lines
of non-immune cell origins have been shown to express
multiple human A3s, such as colorectal hepatocarcinoma,
adenocarcinoma, melanoma and lung carcinoma lines
[(17,27,38,56–59) and http://www.oncomine.org]. It is
possible that A3 expression switches on at some stage
during oncogenesis, but given the abundance of A3si n
cancer cell lines it is likely that part of this reﬂects the
normal gene expression program that existed prior to
immortalization. Thus, the broad and apparently consti-
tutive A3 expression proﬁle of many human tissues is
Nucleic Acids Research, 2010,Vol.38, No. 13 4281consistent with a general role for A3 proteins in innate
immunity. Substrates may not only include endogenous
and exogenous retroelements, but also DNA viruses and
even naked, foreign double-stranded DNA (10–12,60).
Fourth, our data and those of Koning et al. (35) are
somewhat discordant on the relative diﬀerence between
A3G and A3F expression levels. They concluded that the
A3G mRNA levels are 10-fold higher than those of A3F.
In contrast, we did not observe such a large expression
bias. In some tissues such as lung we observed a modest
bias in favor of A3G. Conversely, in other tissues such as
the colon and ovary, we observed a slight bias toward
A3F. However, in general, we observed that A3F and
A3G levels are fairly similar and that these mRNAs are
invariably expressed together. Our data are consistent
with prior A3F and A3G multi-tissue northern blot
results and the fact that the promoter regions of A3F
and A3G are 96% identical over a 5-kb region including
exons 1 and 2 (56). We favor a model in which A3F and
A3G are coordinately expressed [proposed originally by
ref. (56)]. A greater understanding of the promoters and
their associated transcription factors will help provide
future tests of this model. It is possible that diﬀerences
between the results reported here and the literature are
due to protocol diﬀerences such as random primed
versus oligo-dT mediated cDNA synthesis, the latter
being much less eﬃcient and susceptible to repetitive
elements in 30 UTRs, and/or to imperfect PCR reaction
eﬃciencies (e.g. Supplementary Figure S2).
On a strong complementary note, a major point detailed
here and in the study by Koning and coworkers is the
inducibility of A3 mRNA expression. Several prior
studies have examined the IFN-responsiveness of the
A3s and particularly A3G and the conclusions have been
variable (11,35,37–42). However, in agreement with
Koning and coworkers, our data indicate that none of
the A3s are induced by IFN in primary CD4
+ T lympho-
cytes (Figure 4B). Small increases in A3 expression, such
as for A3A, can be attributed readily to a few
contaminating CD14
+ cells in the T lymphocyte prepar-
ations. Rather, the strong IFN responsiveness of the A3s,
highlighted by A3A, may be a property of other blood cell
lineages such as CD14
+ monocytes and macrophages
(11,35,39). We also found that T-cell activation with
IL-2 and PHA causes the induction of 6/7 A3s [i.e. all
but A3A; Figure 4B and refs. (35,36)]. These studies
combine to indicate that cells have multiple mechanisms
to regulate A3 expression. Thus, in addition to constitutive
expression of most of the A3 repertoire in many cell types
and tissues, transcriptional regulation is likely to have a
major role in ultimately determining the eﬃcacy and
potency of A3-dependent defenses against viral and
non-viral challenges.
Overall, turning back to the question of HIV-1 restric-
tion, our studies are consistent with A3F, A3G and po-
tentially several other A3s being important in CD4
+ T
lymphocytes. A3H is the most likely additional restriction
factor because (i) it is expressed in the non-permissive
T-cell line H9 (Figure 2), (ii) it is expressed in naı¨ve
CD4
+ cells (Figure 3), (iii) it is induced 20-fold by T-cell
activation (Figure 3), and (iv) it is capable of HIV-1
restriction in a Vif-susceptible manner (20,51–55).
Although the literature overwhelmingly favors a role for
A3G in HIV-1 restriction, with A3F a distant but
important second, A3H and several of the other A3s
warrant substantive additional investigation.
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